What is HC Wainwright’s Forecast for ACAD Q1 Earnings?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of ACADIA Pharmaceuticals in a research report issued on Thursday, February 27th. HC Wainwright analyst A. Fein forecasts that the biopharmaceutical company will earn $0.10 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q2 2025 earnings at $0.16 EPS, Q3 2025 earnings at $0.20 EPS, Q4 2025 earnings at $0.24 EPS and FY2029 earnings at $2.32 EPS.

Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday. StockNews.com downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Guggenheim downgraded ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the company from $23.00 to $20.00 in a research report on Friday, January 3rd. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They set a “hold” rating and a $22.00 target price on the stock. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $24.00.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ:ACAD opened at $19.60 on Friday. ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $24.53. The stock has a fifty day moving average of $18.37 and a 200-day moving average of $16.81. The company has a market capitalization of $3.26 billion, a PE ratio of 25.13 and a beta of 0.37.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Jefferies Financial Group Inc. acquired a new position in shares of ACADIA Pharmaceuticals in the fourth quarter worth $2,106,000. Mackenzie Financial Corp increased its position in ACADIA Pharmaceuticals by 180.1% during the fourth quarter. Mackenzie Financial Corp now owns 51,065 shares of the biopharmaceutical company’s stock worth $937,000 after buying an additional 32,833 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in ACADIA Pharmaceuticals during the fourth quarter worth $64,000. CTC Alternative Strategies Ltd. acquired a new position in ACADIA Pharmaceuticals during the fourth quarter worth $1,012,000. Finally, Neo Ivy Capital Management increased its position in ACADIA Pharmaceuticals by 1,551.5% during the fourth quarter. Neo Ivy Capital Management now owns 57,504 shares of the biopharmaceutical company’s stock worth $1,055,000 after buying an additional 54,022 shares during the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.